Use of anti‐vascular endothelial growth factor in the management of pterygium

Mak, Renata Kiri; Chan, Tommy C Y; Marcet, Marcus M.; Choy, Bonnie Nga Kwan; Shum, Jennifer; Shih, Kendrick Co; Wong, Ian Yu‐Hong; Ng, Alex

doi:10.1111/aos.13178

Cited by 25 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were obtained in the vascular endothelium and stromal cells of pterygium 40–42. Furthermore, anti-VEGF drugs have been applied in the clinical setting as adjuvants for pterygium treatment and recurrence prevention 43–45. Taken together, we speculate that HDL-C may be involved in the angiogenesis of pterygium via the HIF-1α/VEGF pathway.…”

Section: Discussionsupporting

confidence: 84%

High HDL-C and high LDL-C are risk factors of pterygium in a population-based cross-sectional study in Southern China: the Dongguan Eye Study

et al. 2022

View full text Add to dashboard Cite

ObjectivesTo investigate the relationship between serum lipids and pterygium in a large-scale rural population aged 40 years or older from Southern China.Study designThe Dongguan Eye Study was a cross-sectional population-based study from September 2011 to February 2012.SettingThe area was set in the rural area of Dongguan, Southern China.ParticipantsAdult rural population aged 40 or older.MethodsParticipants underwent physical, haematological and ophthalmic examinations.Primary and secondary outcome measuresThe frequency and risk factors of pterygium.ResultsA total of 11 357 participants were eligible for inclusion and 8952 (78.8%) participants were enrolled for the systemic and ophthalmic examinations. The prevalence of pterygium was 17.3% after adjusting the sex and age distribution, 22.0% in participants with hypercholesterolaemia (total cholesterol ≥6.22 mmol/L (240 mg/dL)) and 21.8% in those with low-density lipoprotein-cholesterol (LDL-C) ≥4.14 mmol/L (160 mg/dL), respectively. After adjusting for multiple confounding factors, higher level of high-density lipoprotein-cholesterol (HDL-C) (OR: 1.23, 95% CI: 1.06 to 1.41) and LDL-C (OR: 1.13, 95% CI: 1.06 to 1.20) were positively associated with the risk of pterygium. The ORs for HDL-C or LDL-C with pterygium were significantly greater in participants aged 40–49 years than those aged 50 years or above (P for interaction <0.001). Furthermore, increased HDL-C showed greater association with pterygium in normal body mass index (BMI) group compared with overweight group (P for interaction=0.002).ConclusionIncreased HDL-C and LDL-C are risk factors of pterygium, especially in people <50 years or those with normal BMI level. Strict control of HDL-C and LDL-C may be a new prevention method in reducing the risk of pterygium.

show abstract

Section: Discussionsupporting

confidence: 84%

High HDL-C and high LDL-C are risk factors of pterygium in a population-based cross-sectional study in Southern China: the Dongguan Eye Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[2][3][4] Since bevacizumab, a known anti-VEGF agent has already been used for the management of vascular endothelial growth factor induced pathologies in the retina, it has been used in pterygium management as well. [5][6][7] Recurrent pterygium has been treated with topical bevacizumab. 8,9 Delay in recurrence and regression of limbal conjunctival neovascularization have been reported with use of subconjunctival bevacizumab.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of subconjuctival bevacizumab injection in the management of pterygium

2020

IJCEO

View full text Add to dashboard Cite

Purpose: To assess the efficacy and safety of sub-conjunctival bevacizumab in the management of grade II and III pterygium. Materials and Methods: Cases of pterygium with no other ocular abnormality and with no systemic disorders were subjected to anterior segment photography and graded. Ten cases of grade III pterygium and eleven cases of grade II pterygium were administered subconjunctival intralesional injection of 2.5mg/0.1ml of bevacizumab. Anterior segment photographs were taken on day 7, day 28 and day 90 along with complete ocular examination and general physical examination. The pterygium vascularity, size and thickness were assessed keeping note of any adverse effects ophthalmic or otherwise. An evaluation of the symptoms before injection and at day 90 was also done. Results: There was statistically significant improvement in the grade, color, intensity, size of pterygium, and symptoms of patients. There was a decrease in symptoms of redness, itching, watering, and irritation. Of the 10 cases with Grade III on enrollment, 08 (80%) had shown a decrease in vascularity with half of them graded as II and the remaining half as grade I. Of the 11 cases of Grade II pterygium at baseline, 05 (45%) cases changed to grade I by day 90. Conclusion: This study revealed that the sub-conjunctival injection of bevacizumab was found to be useful in reduction of symptoms of patients with grade III & II pterygium with no local or systemic adverse effects.

show abstract

“…8 Between Europe in the years 2000 and 2017, the success rate for the surgical treatment of pterygium pterygium with conjunctival autograft ranged from 0% to 14.29%. [9][10][11] In Dakar in 2010, the success rate of pterygium surgery using conjunctival autograft was 88%. 12 The scarcity of literature in West Africa, particularly in Mali, has led to the realization of this study whose aim is to evaluate the preliminary result of pterygium excision with conjunctival autograft at the Infirmary of the Bamako Hospital.…”

Section: Introductionmentioning

confidence: 99%

Surgical treatment of pterygium in melanoderma: Preliminary results of the conjunctival autograft at the infirmary of bamako hospital

Bakayoko¹,

Kolé²,

R³

2020

IJOOO

View full text Add to dashboard Cite

Pterygium is a benign eye disease with varying prevalence in different regions. Ultraviolet light is the main risk factor. The curative treatment is surgical, but it remains incompletely effective with recurrences that are not rare. Many techniques are described alone or combined with adjuvant treatments. The aim of our work is to evaluate the preliminary outcome of pterygial excision with conjunctival autograft. Materials and Methods: A prospective study was carried out between May 2016 and October 2017 in the ophthalmology department of the Bamako Hospital Infirmary. It included 81 patients who had a primary or recurrent pterygium operated on in the department. Results: The average age was 45.74 years. The sex ratio was 1.13 M/F. Of the 81 pterygions operated on, 14.8% were stage IV and 16% recurrent, with nasal localization in 92.6%. Conjunctival hyperhaemia more or less associated with subconjunctival haemorrhage was present until postoperative day 15. We noted 4.9% recurrence. Discussion: There is no consensus in the surgical treatment of pterygions. The technique of removal of the pterygium associated with conjunctival autograft would induce fewer complications and the least recurrence. Conclusion: Early management of pterygium with the autograft technique remains the best therapeutic choice for this condition.

show abstract

Use of anti‐vascular endothelial growth factor in the management of pterygium

Cited by 25 publications

References 33 publications

High HDL-C and high LDL-C are risk factors of pterygium in a population-based cross-sectional study in Southern China: the Dongguan Eye Study

High HDL-C and high LDL-C are risk factors of pterygium in a population-based cross-sectional study in Southern China: the Dongguan Eye Study

Efficacy and safety of subconjuctival bevacizumab injection in the management of pterygium

Surgical treatment of pterygium in melanoderma: Preliminary results of the conjunctival autograft at the infirmary of bamako hospital

Contact Info

Product

Resources

About